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Abstract
Background: Tumors commonly are infiltrated by leukocytes, or tumor infiltrating leukocytes (TILs). It remains unclear,
however, if the density and type of individual TILs has a direct or simply correlative role in promoting poor prognosis in
breast cancer patients. Breast cancer in Kenyan women is aggressive with presentation at a young age, with advanced
grade (grade III), large tumor size (>2.0 cm), and poor prognosis. We previously observed that the tumors were
predominantly estrogen receptor positive (ER+) but also included both a high percentage of triple negative tumors and
also increased immune cell infiltration within the tumors. We used breast tumor tissues from each patient to make tissue
microarrays that were then stained for leukocyte and myeloid markers including CD4, CD8, CD20, CD25, CD68, and
CD163 using immunohistochemical techniques. The immune cell infiltration into the cancer tissue included increased
numbers of macrophages (CD68+), helper T cells (CD4+), and CD25+ lymphocytes compared to benign tissue.
Results: This study characterized the grade, molecular subtypes, and proliferation index of these tumors and determined
if TIL density was enriched across any of these factors. We analyzed 49 malignant patient tissue samples for this study.
The patient population had a mean age of 51.9 years. The tumors analyzed were heterogeneous by grade: grade I (6%),
grade II (47%), and grade III (39%). Most patients presented with large tumors (>2.0 cm) (69%). We classified the tumors
into molecular subtypes based on clinical marker expression. Based on this analysis, the molecular subtype distribution
was heterogeneous with luminal B (41%), basal/triple negative (TN) (37%), luminal A (14%) and HER2 (8%) breast cancer
subtypes. While the basal/TN subtype had a much higher proliferative index (Ki-67+) than did the other molecular
subtypes, we did not see a significant correlation between TIL density and either subtype or tumor grade. Therefore,
TIL density is independent of molecular subtype and grade.
Conclusion: This study identified a Kenyan patient cohort that develops large, high-grade tumors primarily of the luminal
B and basal molecular subtypes. After analyzing the TILs within these tumors, we found that immune cell infiltration of
these tumors correlated with increased proliferation but not grade or molecular subtype. Future research is required
to determine if the aberrant recruitment of TILs to tumors contributes to cancer progression and response to cancer
treatments.
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Background
Ideally, the immune system destroys and inhibits can-
cer. In contrast, suppression of the immune response
can instead promote tumor progression, given the
proper context. Recent research has led to increased
development and application of immunotherapy,
which modulates the immune response, as a cancer
treatment [1, 2]. However, the classification of the
ability of an immune cell to promote or inhibit can-
cer progression can be difficult because the immune
cell function can be influenced by the microenviron-
ment, which includes other immune cells. Indeed,
tumor infiltrating leukocytes (TILs) can be classified
as activated, regulatory, or anergic [3].
Both the TIL type and density contribute to the host
immune response to breast cancer [3]. In cancer, infiltra-
tion of effector T cells correlates with better prognosis
[4–6]. In contrast, infiltration of CD25+ lymphocytes
promotes tumor growth and progression by suppressing
the effector function of cytotoxic cells [7]. Also, CD4+ T
cells in tumors have cellular plasticity with both anti-
and pro-tumor roles [8].
In African patients, breast cancer is diagnosed at a
young age and is aggressive, with tumors that are of ad-
vanced grade, large in size, and a high rate of triple
negative (TN; estrogen receptor negative, ER−; proges-
terone receptor negative, PR−; and human epidermal
growth factor receptor 2 negative, HER2−) [9–11]. The
cause of this aggressive cancer has not been elucidated
but may be related to the immune response of these pa-
tients. Our previous study found that breast cancers of
patients in Kenya had increased immune cell infiltration,
as indicated by increased recruitment of CD163+ (M2
macrophage), CD25+ lymphocytes, and CD4+ (T helper)
cells compared to non-cancer tissue [12].
The immune response in breast cancer patients can
have predictive therapeutic value, especially with re-
sponse to chemotherapy [13]. The presence of or the ra-
tio comparing specific TILs within a tumor may
represent immune homeostasis within the tumor and
the tumor microenvironment [1]. Although the role and
mechanism of the individual TILs in the clinical and
biological behavior of tumor are unclear, TILs seem to
have predictive value for breast tumors in response to
neoadjuvant chemotherapy (NCT) [2, 14]. We previously
found increased tumor infiltration of CD25+ lympho-
cytes in high-grade tumors, which may play a role in
suppressing the adaptive immune response leading to
poor prognosis in this type of tumors, and modulating
these cells could manage aggressive breast cancer types
[12]. Other cells, such as myeloid-derived suppressor
cells in breast cancer (MDSCs), also may have suppres-
sive action on effector cells by making them immuno-
therapeutic agents [15].
The variable density and type of immune cells local-
ized to breast tumors may trigger aberrant immune re-
sponses in these patients. The heterogeneity of recruited
immune cells to the tumors may vary between cancer
subtypes, suggesting that different immune cell popula-
tions may contribute to tumor suppression or other
mechanisms of disease progression or subtype [16]. Al-
ternatively, immune cell recruitment and heterogeneity
may be an independent marker of disease progression
that may be even more relevant to prognosis and/or
treatment. The tumor grade and molecular subtypes of
these tumors as well as the level of recruitment of TILs
within tumors of certain subtypes were not investigated
in our previous study [12]. Therefore, it remains unclear
if the TILs that are recruited to the tumors are potential
markers that correlate with the molecular subtype or are
independent markers of the host immune response. The
current study determined if immune cell infiltration into
the breast tumors from Kenyan patients might be related
to breast cancer subtype and/or tumor grade. Under-
standing the pattern and function of immune cell infil-
tration in aggressive tumors of African women is an
important strategy to better understand the progression
of these tumors. Identifying the significance of the re-
cruitment of these cells in the tumors could form the
basis for the identification of markers that represent the
host’s immune response.
Methods
Study design
This prospective study used consecutively collected
breast tumor samples that have been described previ-
ously [12]. Briefly, all patients with histologically diag-
nosed breast cancer who consented to participation in
this study, who met the inclusion criteria, and were diag-
nosed and treated at the MTRH oncology clinic between
May 2011 and July 2013 were included in this study (N
= 68). Patients were included in the study if they had
pathologically confirmed breast cancer with no history
of chemotherapy. Patients were excluded from this study
if they had benign tumors, if they did not consent to
participation in the study, if they had a history of cancer
prior to the study, or if they used chemotherapy prior to
the study. Tissue microarrays generated from these tu-
mors (described below) were stained for the described
molecular markers. Of the tumor samples on the tissue
microarrays, 49 tumor samples had interpretable stain-
ing for all of the indicated markers. Samples from these
49 patients are the samples analyzed and described in
this paper. This study adhered to appropriate ethical
standards in accordance with approved IRBs from both
the University of Notre Dame (IRB Approval # 13-06-
1102) and Moi University (IRB Approval # 000655).
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Tissue processing
Specimens were fixed in 10% buffered formalin and then
processed through dehydration, xylene, and paraffin in-
filtration steps in an automatic tissue processor Leica TP
1020 (Leica microsystems Nussloch Gmbh Heidelbeger
Sitr. 17-19 D-69226 Nussloch Germany). The blocks
were transferred from MTRH to Notre Dame, where the
samples were re-embedded into melted paraplast X-tra
(McCormick Scientific). Thin sections (3 μm) of tissue
samples were cut using rotary microtone (Letz 1512)
equipped with disposable blades and stained by
hematoxylin and eosin and then analyzed by pathologists.
Construction of tissue microarrays
We made tissue microarrays (TMAs) of the breast tissue
samples [12]. As described, the tissue cores were
punched from donor blocks with a 1-mm-diameter sty-
lus and loaded to recipient paraffin blocks. The design
of the TMAs made it possible to evaluate the frequency
of markers across tumor grades and molecular subtypes
from patient tumors. The TMA layout on the recipient
TMA blocks was designed in advance to include dupli-
cates of each tissue sample and to organize the tissue
samples randomly across the TMAs. Tissue regions were
selected and included in the TMA based on the path-
ology of the tissue determined from the H&E-stained
slides of each tissue block. The TMA blocks were con-
structed with a Veridiam Advanced Tissue Arrayer
VTA-110CC. Blocks were sectioned at 3 μm thickness
with Leica rotary microtome RM2125. Each of the two
TMAs used for the staining had ~100 tissues per block
with duplicates of each tissue sample included across the
two TMAs.
For breast cancer tissue TMAs, including two or more
tissue punches of 1-mm core diameter is preferred over
a single punch or larger punch are more consistent and
representative of the entire tumor [17, 18].
Immunohistochemistry
Tissue sections were dewaxed by placing the sections
on IHC slides at 60 °C for 30 min followed by pro-
cessing the samples through three incubations with
xylene and then alcohol. After deparaffinization and
rehydration in water, the tissues were treated for
heat-induced epitope retrieval (HIER). A working
solution was prepared by diluting the Envision™
FLEX target retrieval solution (50×) concentration
1:50 in distilled water. Pretreatment module (PT
link) was then filled with sufficient quantity (1.5 L)
of working solution to cover the tissue sections, and
then was set to pre-heat the solution to 65 °C. Tis-
sue sections that were already deparaffinized and
rehydrated were immersed to pre-heated Envision
Flex target retrieval solution and incubated for
20 min at 97 °C. Then, the sections were left to cool
in the PT link to 65 °C.
Each slide rack was removed from the PT link tank
and immediately dipped the slides into a jar with a di-
luted room temperature FLEX TM wash buffer (20×)
and left for 1–5 min. Slides were then stained on a Dako
autostainer Plus (Dako Colorado, Inc).
The primary antibodies used for our analysis in-
clude antibodies that recognize estrogen receptor
(ER), progesterone receptor (PR), human epidermal
growth factor receptor 2 (HER2), Ki-67, CD4, CD8,
CD20, CD68, CD163, and CD25 (Table 1). The sec-
ondary antibodies used include EnVision™ Flex+Mouse
(Linker), (Dako) SM804; EnVision™ Flex Peroxidase-
Blocking Reagent (Dako) SM801; EnVision™ Flex/HRP
(Dako) SM802; EnVision™ Flex Antibody Diluent
(Dako) DM830; and Hercep Test™ Peroxidase-
Blocking Reagent (Dako) SK001. The choice of these
markers is supported by the recommendations by the
International TILs Working Group 2014, who advo-
cates the scoring of most mononuclear cells but
excluding polymorphonuclear leukocytes [16].
Table 1 List of primary antibodies
Antibody Vendor/clone Pretreatment Dilution Control tissue Detection/linker Incubation time (minutes)
ER Dako IR084 TRS high pH RTU Breast Ca Flex 20/20/10
PR DakoIR068 TRS low pH RTU Breast Ca Flex + M 20/20/20/10
HER2 Dako SK001 Herceptest antigen retrieval Herceptest Herceptest 30/30/10
Ki-67 DakoIR626 TRS high pH RTU Breast Flex 20/20/10
CD4 DakoIR649 TRS high pH RTU Tonsil Flex + M 15/10/10/10
CD8 DakoIR623 TRS low pH RTU Tonsil Flex + M 15/15/15/10
CD68KPI DakoIR609 TRS high pH RTU Tonsil Flex 20/10/10
CD20 DakoIR604 TRS high pH RTU Tonsil Flex 10/10/10
CD25 NC NCLCD25-305 TRS high pH 1:100 Tonsil Flex + M 15/10/10/10
CD163 Vector Laboratories Inc.VP6017007 TRS high pH 1:100 Bone Marrow Flex + M 15/10/10/10
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Quality control
A known positive control specimen was used in each
staining run to ascertain a proper performance of all the
applied reagents. If a positive control specimen failed to
demonstrate positive staining, labeling of test specimens
were considered invalid hence repeated.
For a negative control, secondary antibody without
primary antibody was used to identify any nonspecific
staining. If the nonspecific staining was not clearly dif-
ferentiated from the specific staining of the test speci-
men that test was considered invalid.
Image analysis
IHC images were quantified with Aperio Image Analysis
Tools software using customized macros from the Color
Deconvolution and Cell Quantification algorithms in the
Aperio Image Analysis Tools software to analyze each
DAB chromogen-stained tissue section. One representa-
tive area from each tissue core of the stained tissue sec-
tions was manually selected with ImageScope annotation
tools and assigned with a position code on the TMA lay-
out for easy identification. After marking all the regions of
interest on a TMA IHC slide, analysis with a proper macro
was run and the output results were exported as an Excel
file for further data organization and processing.
Statistical analysis
Statistical analysis was completed using GraphPad Prism
6.0. Descriptive statistics were used in summarizing stat-
istical results. Ki-67 and TIL markers were compared
across grades and molecular subtype by Kruskal-Wallis
followed by Dunn’s multiple comparison tests. Controls
and those that did not have either grade data or the ap-
propriate staining information to classify the samples by
molecular subtype were excluded in the analysis. Level
of significance was set at p < 0.05.
Results
Grade and molecular subtype determination of Kenyan
breast cancer
The purpose of this study was to begin to determine
the significance of the immune cell infiltration that
we previously described in a prospective study of a
breast cancer patient population from Eldoret, Kenya
[12]. In this study, we compare the immune cell infil-
tration with known molecular subtypes and tumor
grade to determine if these are interrelated or inde-
pendent markers. To do this, we used immunohisto-
chemistry quantification data of clinical markers
(receptor expression and proliferation marker Ki-67
status), TIL density, and pathology that we described
previously [12] (Table 1). We also further investigated
the grade and molecular subtype of these tumor
samples.
Of our malignant patient tissue sample collection
(N = 68), 49 of these samples were determined to have
been stained and analyzed for expression of all of the
markers described in the current study [12]. These 49
samples were used in the analysis for the current
study. At presentation of disease, the patients in-
cluded in our study had an average age of 51.9 years
old and median age of 48.5 years old (standard devi-
ation, 17.3) (Table 2).
Most of the patients presented with large tumors
(>2.0 cm) (69%) that were primarily ER positive (ER+
59%), PR negative (PR− 60%), and HER2 negative (HER2
− 86%) by immunohistochemistry (Table 2). The tumors
were highly proliferative (88%), as determined by a high
percentage of Ki-67 positively stained cells. In addition,
the grade of the tumors analyzed was heterogeneous:
grade I (6%), grade II (47%), and grade III (39%).
We classified each patient tumor into a molecular sub-
type based on the expression of clinical markers
(Table 3). The molecular breast cancer subtypes were
identified as described previously [19]. The luminal B
(41%) and basal/triple negative (TN) breast cancer
Table 2 Demographics and clinical characteristics of the study
group (N = 53)
Variable Number Percentage
Mean age at diagnosis, 51.9 years
Median age at diagnosis, 48.5 years
Standard deviation, 17.3
Tumor grade
I 3 6
II 23 47
III 19 39
Not graded 4 8
Tumor size (cm)
≤2 8 31
2.1–5 11 42
>5 7 27
ER
Positive 29 59
Negative 20 41
PR
Positive 19 40
Negative 29 60
HER2
Positive (3) 7 14
Negative (0–2) 42 86
Ki-67
<14% (low) 6 12
≥14% (high) 43 88
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subtypes (37%) included the majority of the tumors.
Luminal A (14%) and HER2 (8%) subtype tumors were
less frequent. This distribution is similar to that seen in
other African populations [9, 10]. These data also are
comparable to reports from the USA and western coun-
tries [20, 21].
Proliferation varies by molecular subtypes
In breast cancer, proliferation as marked by high expres-
sion of Ki-67 varies by subtype [19, 22–24]. Breast can-
cers with high proliferation (proliferative marker Ki-67
≥14%) are associated with poor patient prognosis [25].
We examined proliferation within the tumor subtypes
and grades. Ki-67 varied across the molecular subtypes
(p = 0.0009; Kruskal-Wallis) and was enriched most
significantly in the basal/TN molecular subtype and in
ER-negative tumors (Fig. 1). This suggests that basal/TN
tumors and ER negative had a higher proliferative cap-
acity than did the other subtypes. In contrast, Ki-67 did
not significantly vary across grades (p = 0.1241) (Fig. 1).
We next determined if the TIL infiltration densities
were related to the proliferative capacity of the tumors
by comparing TIL density with Ki-67 proliferation index.
We found statistical significance in the correlation be-
tween Ki-67 status and CD68, CD163, and CD25 with a
similar trend for CD4 (Fig. 2). These data suggest that
these immune cells in particular are related to the high
proliferative capacity of the tumors.
Proliferation and tumor infiltrating leukocytes (TILs) in
relation to molecular subtypes
To determine if the immune response actually con-
tributes to the aggressive phenotypes commonly seen
in this patient population and that are represented by
subtypes, we determined if the levels of immune cell
infiltrates correlated with grade and molecular sub-
types of breast cancer. We determined if proliferation
and individual TILs localized to the tumor tissue were
enriched within particular breast cancer molecular
subtypes. We found no statistical significance between
the density of TILs across grades (Fig. 3) or across
Table 3 Molecular subtypes
Variable Characteristics N (%)
Luminal A ER+ and/or PR+, HER2−, low Ki-67 7 (14)
Luminal B ER+ and/or PR+, HER2+ (or HER2− with high Ki-67) 20 (41)
Her2 ER− and/or PR-, Her2 + Any Ki-67 4 (8)
Basal/triple
negative
ER−, PR−, HER2− and any Ki-67 18 (37)
ER+/- estrogen receptor positive or negative, PR+/- progesterone receptor
positive or negative, HER2 +/- human epidermal growth factor positive
or negative
Fig. 1 Ki-67 status in Kenyan breast tumors by molecular subtype and grade. Breast cancer tissue samples were stained for Ki-67 and scored for
percent Ki-67-positive cells. Ki-67 status then was compared across molecular subtype (a) by Kruskal-Wallis (P = 0.0009) followed by Dunn’s multiple
comparison tests, ER status (b) by Mann-Whitney (P = 0.006), and grade (c) by Mann-Whitney (P = 0.1241) (the P value is indicated by
* and ** for P < 0.05 and P<0.01, respectively)
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the different molecular subtypes (Fig. 4). This sug-
gests that the TIL density does not correlate with
molecular subtype or grade and that immune cell in-
filtration is not simply a surrogate for grade or sub-
type. Instead, TIL infiltration is an independent
marker and another factor, which currently is un-
known, must cause the changes in the immune re-
sponse and correlate with the data.
Discussion
This prospective study determined that TIL infiltra-
tion is an independent marker of breast cancer in
these tumors. Our results indicate that TIL infiltra-
tion is independent of grade and subtype. In our pre-
vious study, we began to characterize the breast
cancer seen in patients in Western Kenya. We
discovered that these tumors were aggressive with
high proliferation and increased immune cell infiltra-
tion [12]. In this study, we further classified the grade
and molecular subtype of tissue from Kenyan breast
cancer patients treated in a regional hospital setting
and evaluated TILs as an independent marker of
breast cancer in these patients. Using immunohisto-
chemistry molecular markers, we classified these tu-
mors by molecular subtypes. These tumors are
heterogeneous with most tumors classified as luminal
B (41%) and basal/TN (37%) subtypes. To further
study the immune cell infiltration, we determined if
the density of individual TILs varied across molecular
subtypes and grade or was independent of these. Our
results indicate that TIL densities did not significantly
correlate with the cancer subtype and tumor grade.
Fig. 2 Ki-67 and TIL density correlate in breast tumors from Kenya. Breast cancer tissue samples were stained for TILs, including CD68, CD163,
CD4, CD8, CD20, and CD25. Each sample was scored for percentage of positively stained area for the indicated TIL. The Ki-67 positively stained
areas/nuclei then were compared across TIL expression levels of CD68 a, CD163 b, CD4 c, CD8 d, CD20 e, and CD25 f by Spearman
correlation (P = 0.02, 0.003, 0.057, 0.16, 0.52, and 0.0096 with r = 0.3419, 0.4023, 0.2741, 0.2140, 0.09378, and 0.3704, respectively)
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Therefore, while immune cell infiltration significantly
correlates with malignancy in these tumors, this infil-
tration is independent of the molecular subtype or
tumor grade.
Even though in our study we saw no significant differ-
ence in immune cell infiltration in tumors across most
molecular subtypes, the individual TILs could hold clin-
ical value as a marker that is independent of subtype
and instead applicable across all subtypes but specific to
treatment (e.g., chemotherapy-resistant tumors). In
breast cancer, infiltration of breast tumors by effector T
cells correlates with better prognosis [5, 6, 26]. In con-
trast, infiltration of CD25+ regulatory T cells promotes
tumor growth and progression by suppressing the ef-
fector function of cytotoxic cells [7]. Also, CD4+ T cells
in tumors have plasticity and have both anti- and pro-
tumor roles [8]. In contrast to our current study, which
finds no significant differences in immune cell density
between tumor grades, other studies demonstrate differ-
ential lymphocyte infiltration in breast cancer tissues
based on histological grade, with infiltration by CD4+
and CD8+ Th1 effector cells in lower grade tumors
[3, 27]. However, the immune cell heterogeneity and,
more specifically, the ratio of immune cells to other im-
mune cells within a tumor may be critical in identifying
any contribution of these cells to patient prognosis.
One limitation of this study could be the use of TMAs
rather than the entire tissue sections for TIL and mo-
lecular marker analysis. However, we have tried to miti-
gate this concern by using multiple tissue punches per
tissue sample per TMA. When using TMAs of breast
cancer tissue, including two or more tissue punches of
Fig. 3 The density of TILs does not differ between tumor grades in breast tumors from Kenya. Breast cancer tissue samples were stained for TILs,
including CD68, CD163, CD4, CD8, CD20, and CD25. Each sample was scored for percentage of positively stained area for the indicated TIL. The
positively stained areas then were compared across tumor grades 1 & 2 and 3 by Mann-Whitney CD68 a, CD163 b, CD4 c, CD8 d, CD20 e, and CD25 f
(P = 0.98, 0.56, 0.73, 0.29, 0.68, and 0.47, respectively). The stained area did not significantly vary by grade
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1-mm core diameter is preferred and is shown to be
more consistent and representative of the entire tumor
compared to either a single punch or a larger 2-mm core
punch [17, 18]. In our analysis, we included duplicate
tissue punches (1-mm core diameter) from each tumor
sample to increase the likelihood that the data was rep-
resentative of the entire tissue. In addition, our analysis
scored the number of TILs per cancer tissue and imme-
diately adjacent stroma on a TMA but did not include
TMA samples that were predominantly stromal tissue,
rather than a cancer-cell-containing tissue. This ap-
proach might self-select for a subset of the TIL
population and could more appropriately be analyzed by
flow cytometry analysis from fresh tissues of single-cell
suspensions that are stained and analyzed for TIL
markers. However, this option was not available for this
study.
The small sample size was a limitation of this study.
Our patient population included very few tumors classi-
fied as HER2 positive (14%) by immunohistochemistry
or as HER2 (8%) by molecular subtype (Tables 2 and 3).
For example, due to the small numbers of HER2+ sam-
ples, we are unable to draw conclusions about the Ki-67
status of HER2+ tumors within our patient cohort.
a b
c d
e f
Fig. 4 The density of TILs does not differ between molecular subtypes in breast tumors from Kenya. Breast cancer tissue samples were stained for TILs,
including CD68, CD163, CD4, CD8, CD20, and CD25. Each sample was scored for percentage of positively stained area for the indicated TIL. The positively
stained area then was compared across molecular subtypes basal/TN, HER2, luminal A, and luminal B. The positively stained areas then were compared across
molecular subtypes basal/TN, HER2, luminal A, and luminal B by Kruskal-Wallis followed by Dunn’s multiple comparison tests CD68 a, CD163 b, CD4 c, CD8 d,
CD20 e, and CD25 f (P= 0.1187, 0.3502, 0.0898, 0.6775, 0.1376, and 0.3128, respectively). The stained areas did not significantly vary by molecular subtype
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However, for most other analysis of our data, our patient
cohort is sufficiently large to have statistical power. In
addition, our breast cancer patient sample size is com-
parable to other breast cancer studies from Kenya,
Uganda, and Tanzania [28–30]. In fact, a large meta-
analysis of African breast cancer studies did not find a
small study bias in the studies analyzed from sub-
Saharan Africa, which includes Kenya [31]. In compari-
son to these other studies, our study was strengthened
by being a prospective study and by not being a conveni-
ence sample.
Our data do not rule out the possibility of TILs having a
prognostic role in breast cancer progression or a predict-
ive role in response to therapy, since our study did not in-
clude patient outcome or therapeutic response data. This
study will form the basis for future prognostic studies in
African breast cancer patient populations. Since a signifi-
cant percentage of Kenyan breast cancer patients present
with aggressive breast tumors and have poor prognosis,
these patients may not benefit from standard therapies
and may require alternative therapies, such as immune
therapy. For example, the significant population of pa-
tients with TN breast cancer has limited treatment op-
tions. Triple negative breast cancer (TNBC) is a
heterogeneous disease often characterized by aggressive
biology and poor prognosis. Efforts to precisely treat TNBC
have been compounded by the lack of specific therapeutic
molecular targets. Also, in westernized treatment facilities,
patients with HER2+ tumors generally are treated with
trastuzumab. However, the Kenyan community has limited
resources to provide expensive trastuzumab treatment in
such a setting where most patients have few treatment op-
tions; treatment options will depend on markers that accur-
ately will predict response to treatment. Interestingly, CD8+
and CD25+ could be such markers, since TILs are associ-
ated with improved distant metastases-free survival as well
as increased rates of pathological complete response (pCR)
after neoadjuvant trastuzumab and chemotherapy in pa-
tients with HER2-positive breast tumors [6, 32]. In addition,
including Ki-67 in the standard pathological assessment
could help to identify and treat aggressive tumors as early
as possible.
Since we identify TIL density as being independent
of grade and subtype but correlative with prolifera-
tion, this study remains consistent with our hypoth-
esis that the TIL infiltrate may be a reasonable
marker of immune response, thus suggesting immune
modulators as potential therapies that may have effi-
cacy in treating Kenyan breast cancer patients. Future
studies will determine the role of immune cell infil-
trates in a patient’s response to treatment. Since
chemotherapy is the primary line of therapy for
treatment-resistant breast cancers, alternative immu-
nomodulatory treatments may be the second-line
therapies for these patients. By understanding the im-
mune response generated by the tumors, we may bet-
ter understand which immunotherapy treatment
options would be relevant to treating these tumors.
Understanding the pattern and function of immune
cell infiltrates in aggressive tumors of African women
is a step towards identifying the critical immune cells
that could be therapeutic targets in this population
and could be suggestive of potential therapeutic strat-
egies aimed at reprogramming the immune response
in this patient population.
Conclusion
In conclusion, we report that in the tumors of our de-
scribed Kenyan breast cancer patient cohort, immune
cell infiltration measured by the cell type and density of
tumor infiltrating leukocytes in breast tumors correlates
with increased proliferation. However, TIL infiltration
does not significantly vary by breast cancer molecular
subtypes or by grade. Future studies that collect both
additional breast tumor samples as well as longitudinal
survival data from patients will be required to determine
the prognostic value of our findings.
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